en · de · es · fr · pt
selank-notes.peptides6579.com › Guide › Origins And Proposed Mechanisms — Evidence Review

Origins And Proposed Mechanisms — Evidence Review

By Editorial Desk · published 2025-08-05 · last reviewed 2025-08-26 · Guide

A practical reference on peptidase: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-08-26. Anything still debated is marked as such rather than presented as settled.

Origins and Proposed Mechanisms

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Mechanism and Evidence Status

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Free peptide form
Molecular massAbout 751.9 DaCalculated average mass
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form TKPRPGP
Structural basisTuftsin analogueExtended version of a natural tetrapeptide
Development originRussian Academy of SciencesWork carried out from the 1980s onward

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Related pages on this site

Proposed Mechanisms and Research Endpoints

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Background from the literature

By the mid-1990s, several GH companies had sponsored or publicized research into the quality of life of adults with severe GH deficiency. Most were people having been treated with GH in childhood for severe deficiency. Many of them stopped injections as they reached their final heights in the low-normal range. However, as adults in their 30s and 40s, these people, who had been children with growth hormone deficiency, were now adults with growth hormone deficiency and had more than their share of common adult problems: reduced physical, mental, and social energy, excess adipose and diminished muscle, diminished libido, poor bone density, higher cholesterol levels, and higher rates of cardiovascular disease. Research trials soon confirmed that a few months of GH could improve nearly all of these parameters. However, despite marketing efforts, most GH-deficient adults remain untreated. Though GH use was slow to be accepted among adults with GH deficiency, similar research to see if GH treatment could slow or reverse some of the similar effects of aging attracted much public interest. The most publicized trial was reported by Daniel Rudman in 1990. As with other types of hormone supplementation for aging (testosterone, estrogen, DHEA), confirmation of benefit and accurate understanding of risks has been only slowly evolving. In 1997, Ronald Klatz of the American Academy of Anti-Aging Medicine published Grow Young With HGH: The Amazing Medically Proven Plan To Reverse the Effects Of Aging, an uncritical touting of GH as the answer to aging.

Boodikka appears in Green Lantern: First Flight, voiced by Tricia Helfer. This version is an ally of Sinestro who is later killed in a fight with Hal Jordan and Kilowog. Boodikka makes a cameo appearance in Green Lantern: Emerald Knights, voiced again by Grey DeLisle. Boodikka makes a cameo appearance in Green Lantern (2011).

During pregnancy, especially during the first trimester, consumption of retinol in amounts exceeding 4,500 μg/day increased the risk of birth defects, but not below that amount, thus setting a "No-Observed Adverse-Effect Level" (NOAEL). Given the quality of the clinical trial evidence, the NOAEL was divided by an uncertainty factor of 1.5 to set the UL for women of reproductive age at 3,000 μg/day of preformed vitamin A. For all other adults, liver abnormalities were detected at intakes above 14,000 μg/day. Given the weak quality of the clinical evidence, an uncertainty factor of 5 was used, and with rounding, the UL was set at 3,000 μg/day. For children, ULs were extrapolated from the adult value, adjusted for relative body weight. For infants, several case studies reported adverse effects that include bulging fontanels, increased intracranial pressure, loss of appetite, hyperirritability and skin peeling after chronic ingestion of the order of 6,000 or more μg/day. Given the small database, an uncertainty factor of 10 divided into the "Lowest-Observed-Adverse-Effect Level" (LOAEL) led to a UL of 600 μg/day.

List of chancellors of Germany by time in office Religious affiliations of chancellors of Germany List of vice-chancellors of Germany Leadership of East Germany List of monarchs of Germany List of presidents of Germany Minister-Presidents of the French "Saar protectorate"

Sources: en.wikipedia.org

Further detail

That's my privates right there.” Indeed so." Paul Dailly of TV Fanatic gave the episode a 4.15 star rating out of 5 and wrote, "After feeling a little short-changed about excluding characters we've grown to love from The Righteous Gemstones Season 4 Episode 1, the follow-up made up for it in a big way." Hawk Ripjaw of TV Obsessive wrote, "After last week’s compelling prelude episode that focused on the advent of the family, The Righteous Gemstones S4E2, “You Hurled Me Into the Depths, Into the Very Heart of the Seas,“ catches us up with the Gemstones proper, as the family prepares for a birthday telethon to honor the late Aimee-Leigh. And, as expected, the return to the modern Gemstone shenanigans is as hilarious as it’s ever been."

== Treatment == MCTD has no specific treatment. Management should address the individual's primary issues, such as arthritis, skin disease, or visceral involvement. Low-dose glucocorticoids, nonsteroidal anti-inflammatory medications, hydroxychloroquine, or a combination of these therapies can effectively treat many patients. Fever, tiredness, unspecific arthralgias, or myalgias are commonly treated with nonsteroidal anti-inflammatory medications (NSAIDs), hydroxychloroquine, or a low dose of prednisone, depending on the severity. Mild joint involvement can be effectively treated with NSAIDs, hydroxychloroquine, and oral prednisone. Methotrexate has been observed to be useful in more severe cases. If methotrexate is contraindicated, alternative disease-modifying medications for RA, such as leflunomide or azathioprine, may be used. High dosages of corticosteroids are typically effective in treating acute severe myositis. Topical steroids, prednisone, and/or hydroxychloroquine are useful in treating SLE-like skin rash, oral ulcers, and photosensitivity. Steroid treatment is often effective in treating sclerodermatous skin symptoms. Raynaud's phenomenon in MCTD typically responds to vasodilator therapy such as calcium channel blockers, as well as preventive measures including avoiding cold temperatures, smoking, and sympathomimetic drugs. Warming and protecting the fingers are also important. Recent breakthroughs have increased the therapy choices available to people with pulmonary hypertension.

==== Modulation of mitochondrial activity ==== Cannabinoids influence mitochondrial processes, including calcium regulation, apoptosis, electron transport chain activity, mitochondrial respiration and ATP production. Mitochondrial dynamics—encompassing the processes of fusion and fission, as well as alterations in morphology and organelle mobility, are also affected by cannabinoid exposure. In addition, cannabinoids have been shown to modulate mitochondrial biogenesis through the dysregulation of PGC-1α levels. These effects are complex, involving direct membrane interactions and receptor-mediated pathways, but a unified hypothesis is lacking due to conflicting data.

Early settlers were introduced by Native Americans to foods such as turkey, sweet potatoes, corn, squash, and maple syrup. Of the most enduring and pervasive examples are variations of the native dish called succotash. Early settlers and later immigrants combined these with foods they were familiar with, such as wheat flour, beef, and milk, to create a distinctive American cuisine. New World crops, especially pumpkin, corn, potatoes, and turkey as the main course are part of a shared national menu on Thanksgiving, when many Americans prepare or purchase traditional dishes to celebrate the occasion. Characteristic American dishes such as apple pie, fried chicken, doughnuts, french fries, macaroni and cheese, ice cream, hamburgers, hot dogs, and American pizza derive from the recipes of various immigrant groups. Mexican dishes such as burritos and tacos preexisted the United States in areas later annexed from Mexico, and adaptations of Chinese cuisine as well as pasta dishes freely adapted from Italian sources are all widely consumed. American chefs have had a significant impact on society both domestically and internationally. In 1946, the Culinary Institute of America was founded by Katharine Angell and Frances Roth. This would become the United States' most prestigious culinary school, where many of the most talented American chefs would study prior to successful careers. The United States restaurant industry was projected at $899 billion in sales for 2020, and employed more than 15 million people, representing 10% of the nation's workforce directly.

=== State-level regulation === State laws significantly influence the availability and scope of DTC testing services. Federal regulations require the laboratory to have a "written or electronic request for patient testing from an authorized person," but the regulations do not define "authorized person." Thus it is up to each state to determine who is an authorized person.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank made of?

It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.

Is Selank a naturally occurring substance?

The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.

Which receptors does it act on?

No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

Network